TY - JOUR
T1 - Reversions of QuantiFERON-TB Gold Plus in tuberculosis contact investigation :
T2 - A prospective multicentre cohort study
AU - Trigo-Daporta, Matilde
AU - Anibarro, Luis
AU - Ruiz-Serrano, María Jesús
AU - Grijota-Camino, Maria D.
AU - Sabria, Josefina
AU - Garcia-De-Cara, Erika Inés
AU - Domínguez-Castellano, Ángel M.
AU - Rabuñal, Ramón
AU - Penas-Truque, Antón
AU - Pomar, Virginia
AU - Rodríguez, Sara
AU - Santos, María Jesús
AU - Martos, Carmen
AU - Santin, M.
AU - Cebollero, Alba
AU - Alcaide, Fernando
AU - Gijón-Vidaurreta, Paloma
AU - García-Gasalla, Mercedes
AU - Pérez-Recio, Sandra
AU - Moga, Esther
PY - 2023
Y1 - 2023
N2 - Interferon-y Release Assays (IGRA) reversions have been reported in different clinical scenarios for the diagnosis of tuberculosis (TB) infection. This study aimed to determine the rate of QuantiFERON-TB Gold Plus (QFT-Plus) reversions during contact investigation as a potential strategy to reduce the number of preventive treatments. Prospective, multicentre cohort study of immunocompetent adult contacts of patients with pulmonary TB tested with QFT-Plus. Contacts with an initial positive QFT-Plus (QFT-i) underwent a second test within 4 weeks (QFT-1), and if negative, underwent a repeat test 4 weeks later (QFT-2). Based on the QFT-2 result, we classified cases as sustained reversion if they remained negative and as temporary reversion if they turned positive. We included 415 contacts, of whom 96 (23.1%) had an initial positive test (QFT-i). Following this, 10 had negative QFT-1 results and 4 (4.2%) of these persisted with a negative result in the QFT-2 (sustained reversions). All four sustained reversions occurred in contacts with IFN-γ concentrations between ≥0.35 and ≤0.99 IU•mL-1 in one or both QFT-i tubes. In this study, TB contact investigations rarely reveal QFT-Plus reversion. These results do not support retesting cases with an initial positive result to reduce the number of preventive treatments.
AB - Interferon-y Release Assays (IGRA) reversions have been reported in different clinical scenarios for the diagnosis of tuberculosis (TB) infection. This study aimed to determine the rate of QuantiFERON-TB Gold Plus (QFT-Plus) reversions during contact investigation as a potential strategy to reduce the number of preventive treatments. Prospective, multicentre cohort study of immunocompetent adult contacts of patients with pulmonary TB tested with QFT-Plus. Contacts with an initial positive QFT-Plus (QFT-i) underwent a second test within 4 weeks (QFT-1), and if negative, underwent a repeat test 4 weeks later (QFT-2). Based on the QFT-2 result, we classified cases as sustained reversion if they remained negative and as temporary reversion if they turned positive. We included 415 contacts, of whom 96 (23.1%) had an initial positive test (QFT-i). Following this, 10 had negative QFT-1 results and 4 (4.2%) of these persisted with a negative result in the QFT-2 (sustained reversions). All four sustained reversions occurred in contacts with IFN-γ concentrations between ≥0.35 and ≤0.99 IU•mL-1 in one or both QFT-i tubes. In this study, TB contact investigations rarely reveal QFT-Plus reversion. These results do not support retesting cases with an initial positive result to reduce the number of preventive treatments.
KW - Prospective Studies
KW - Tuberculosis
KW - Humans
KW - Adult
KW - Tuberculosis, Pulmonary
KW - Cohort Studies
KW - Latent Tuberculosis
U2 - 10.1371/journal.pone.0285917
DO - 10.1371/journal.pone.0285917
M3 - Article
C2 - 37647315
SN - 1932-6203
VL - 18
JO - PLoS ONE
JF - PLoS ONE
IS - 8 August
ER -
